A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Clinical trial NCT00737529 · COMPLETED

Trial details

NCT number: NCT00737529
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Mantle Cell Lymphoma

Start date: 2008-12-22
Primary completion: 2016-04-06
Enrollment: 134

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.